Back to News
Market Impact: 0.25
Kiora Pharmaceuticals, Inc. Enters Exclusive License Agreement with Senju Pharmaceutical Co., Ltd. for KIO-401
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
On October 23, 2026, Kiora Pharmaceuticals entered an exclusive license agreement with Senju Pharmaceutical for KIO-401, a late-stage neuroprotective oral small-molecule calpain inhibitor. The agreement is effective October 5; the available article text provides no financial terms or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
KPRX0.65
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- PC chip plunge wipes out a quarter of Intel’s value
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up